Mid-Stage Win for Novel IgA Nephropathy Drug
(MedPage Today) -- PHILADELPHIA -- An investigational humanized IgG2 monoclonal antibody reduced proteinuria in adults with immunoglobulin A (IgA) nephropathy at high risk for disease progression despite standard treatments, a randomized phase... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 2, 2023 Category: Urology & Nephrology Source Type: news

Proteinuria Higher With Dasatinib Exposure in Chronic Myelogenous Leukemia
WEDNESDAY, Sept. 20, 2023 -- For patients with chronic myelogenous leukemia (CML) receiving tyrosine-kinase inhibitor therapy, exposure to dasatinib is associated with increased odds of proteinuria, according to a study published online in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2023 Category: Pharmaceuticals Source Type: news

What Are the Complications of Sickle Cell Trait?
Discussion Sickle cell disease (SCD) is a group of inherited blood disorders where there are abnormal hemoglobin molecules and the red blood cells take on a characteristic sickled shape instead of a rounded shape. Sickled hemoglobin provides an evolutionary advantage of giving the individual increased protection against severe and cerebral malaria. The sickled shape doesn’t move through the vascular system as well and therefore is more likely to aggregate in small vessels causing an increased risk of vaso-occlusive disease, acute chest syndrome, splenic sequestration, and priapism. There is also an increased risk of ...
Source: PediatricEducation.org - September 4, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Acute kidney injury in COVID-19 patients admitted at a tertiary care centre: a descriptive cross-sectional study - Manandhar D, Manandhar DN, Chhetri PK, Acharya N, Yogi RN, Upreti AR, Yadav RS, Shrestha N, Joshi S.
This study aimed to find out the prevalence of acute kidney injury in patients... (Source: SafetyLit)
Source: SafetyLit - May 22, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Nonimmunosuppressive Therapy Bests ARB for Cutting Proteinuira in IgA Nephropathy
(MedPage Today) -- AUSTIN, Texas -- Once-daily sparsentan (Filspari) was better at reducing proteinuria than standard treatment in IgA nephropathy, according to a prespecified interim analysis of the PROTECT trial. By week 36 of treatment in... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 16, 2023 Category: Cardiology Source Type: news

What is PAN?
Discussion Vasculitis is an inflammation of the blood vessels. Often, the term implies the arterial vessels, but venous and capillary vessels can be affected. The nomenclature to describe vasculitis and its classification have varied over time. Arterial vessel size is one method and some more common entities include: Small vessel, mainly Granulomatous – granulomatosis with polyangiitis (aka Wegener’s granulomatosis), eosinophilic granulomatosis with polyangiitis (aka Churg Strauss syndrome) Nongranulomatous – Henoch-Schonlein purpura (HSP), microscopic polyangiitis Medium vessel, mainly Childhood sys...
Source: PediatricEducation.org - February 27, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

FDA OKs Sparsentan for IgA Nephropathy-Related Proteinuria
(MedPage Today) -- The FDA granted accelerated approval to sparsentan (Filspari) for proteinuria in IgA nephropathy, Travere Therapeutics announced, marking the first non-immunosuppressive therapy for this rare condition. Also known as Berger... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 21, 2023 Category: Primary Care Source Type: news

FDA Grants Accelerated Approval to Filspari (sparsentan) for the Reduction of Proteinuria in IgA Nephropathy
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients with IgA nephropathy (IgAN) Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a rapid, sustained and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 17, 2023 Category: Drugs & Pharmacology Source Type: news

Oral Steroid Safely Treats IgA Nephropathy: Trial Published Oral Steroid Safely Treats IgA Nephropathy: Trial Published
Delayed-release budesonide reduced proteinuria in patients with primary IgA nephropathy in a pivotal trial, which led to an FDA accelerated approval in December 2021 for the orphan drug.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 25, 2022 Category: Allergy & Immunology Tags: Nephrology News Source Type: news

Real-World Data Links Rosuvastatin to Adverse Effects on Kidneys
THURSDAY, Aug. 18, 2022 -- Rosuvastatin is associated with increased risks for hematuria, proteinuria, and kidney failure with replacement therapy (KFRT) compared with atorvastatin use, according to a study published online July 19 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 18, 2022 Category: Pharmaceuticals Source Type: news

Protein in urine (proteinuria)
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - May 5, 2022 Category: Consumer Health News Source Type: news

Normalized Hypothyroidism Linked With Improved Kidney Function Normalized Hypothyroidism Linked With Improved Kidney Function
Among patients with hypothyroidism but normal kidney function, proteinuria and serum creatinine levels were decreased, and eGFR was increased after levothyroxine-produced euthyroidism in a small study.First Look (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 18, 2022 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

Novel Drug Cuts Proteinuria in APOL1-Mediated Kidney Disease
(MedPage Today) -- An investigative treatment targeting APOL1 activity significantly improved proteinuria APOL1-mediated kidney disease (AMKD), a proof-of-concept phase IIa study found. In a single-arm, open-label study, treatment with oral VX... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - April 10, 2022 Category: Urology & Nephrology Source Type: news

TARPEYO & lt;sup & gt;TM & lt;/sup & gt; (budesonide) delayed release capsules, FDA Approved to Reduce Proteinuria in IgA Nephropathy, Available Exclusively at Biologics by McKesson
CARY, N.C., Dec. 22, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Calliditas Therapeutics as the exclusive specialty pharmacy provider for TARPEYOTM (budesonide) delayed release capsules to reduce proteinuria in adults... (Source: McKesson News)
Source: McKesson News - December 22, 2021 Category: Information Technology Source Type: news

Oral Steroid Gets FDA Approval for IgA Nephropathy Oral Steroid Gets FDA Approval for IgA Nephropathy
Oral budesonide delayed-release (Tarpeyo) became the first agent to receive FDA approval for reducing proteinuria in patients with primary IgA nephropathy and at risk for rapid progression.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 17, 2021 Category: Drugs & Pharmacology Tags: Nephrology News Alert Source Type: news